Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ProCervix plus imiquimod for clearance of HPV 16/18 infection
2013-003358-25Phase 2Completed
- Sponsor
- Genticel
- Start
- Oct 2013
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human papillomavirus infection comparing ProCervix plus imiquimod with Placebo plus imiquimod (2 arms). Started Oct 2013; status: completed.
02
Drugs
GTL001imiquimod
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on 2013-003358-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003358-25.